Recent Updates
Recently added Catalysts

Canakinumab pre-filled syringe

Phase 3

Acute Gouty Arthritis | Small molecule | Musculoskeletal |Novartis AG|Last Updated: Jan 29, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment397
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01356602Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis PatientsPHASE3 COMPLETED 397May 1, 2011Sep 1, 2012Jan 29, 201499 United States, Canada +3
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups
72 hours post dose

The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Missing pain intensity data at 72 hours was imputed using the Last-Observation-Carried-Forward (LOCF) method.

Secondary Endpoints
Pain Intensity on a 0 - 100 mm VAS Between the Canakinumab 150 mg PFS and Canakinumab 150 mg LYO Groups
72 hours post dose
Patient's Assessment of Pain Intensity on a 0-100mm VAS
14 days
Patient's Assessment of Pain Intensity on a 5-point Likert Scale
72 hours
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Canakinumab, pre-filled syringes (PFS)EXPERIMENTALPatients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
Canakinumab, lyophilizate (LYO)ACTIVE_COMPARATORThe patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
Triamcinolone AcetonideACTIVE_COMPARATORThe patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
Interventions
NameTypeDescription
Canakinumab pre-filled syringeDRUGCanakinumab pre-filled syringe
Canakinumab lyophilized powderDRUGCanakinumab lyophilized powder
Triamcinolone AcetonideDRUGTriamcinolone Acetonide
PlaceboDRUGMatching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 85 Years
SexALL
Healthy VolunteersNo
Study Sites99

Inclusion criteria: * 3 or more gout flares within last year * Contraindication, intolerance or lack of efficacy for NSAIDs and/or colchicine * Body mass index of less than or equal to 45 kg/m2 Exclusion criteria: * Use of the following therapies (within varying protocol defined timeframes): cort...

Countries:United StatesCanadaGermanyHungaryLithuania
Unlock Eligibility Criteria